文献速递肾移植

减少肾移植可及性差异区域研究:美国东南部随机试验

Reducing Disparities in Access to Kidney Transplantation Regional Study: A Randomized Trial in the Southeastern United States.
PubMed 文献 · Clin J Am Soc Nephrol · 2024-12-13

该研究在美国东南部三州440家透析机构随机分组,评估多组分干预对早期肾移植步骤可及性的效果。干预后转诊率在两组均下降,但对照组降幅更大(11.2%至9.2% vs 干预组11.2%至10.5%)。黑人患者转诊无显著改善(aOR 1.12,95%CI 0.94-1.33),白人患者转诊显著增加(OR 1.24,95%CI 1.02-1.51)。

要点

  • 干预后转诊率整体下降,但干预组降幅小于对照组。
  • 黑人患者转诊未显著改善,白人患者转诊显著增加。
  • 定性访谈强调定制干预、联邦指令和实施挑战的重要性。

核心结论

  • 干预后转诊率下降反映全国趋势,但部分干预组患者降幅较小,需长期随访。
  • 干预未显著改善黑人患者转诊,但显著增加白人患者转诊。

研究设计与样本

  • 2018年随机对照试验,纳入佐治亚、北卡罗来纳、南卡罗来纳三州440家透析机构。
  • 干预组接受减少肾移植可及性差异的教育与质量干预,对照组接受标准治疗。
  • 主要结局为干预后透析开始1年内机构层面转诊变化,次要结局包括转诊后6个月内开始评估及评估后1年内进入等待名单。
  • 过程评估包括实施后调查(N=220)和工作人员半结构化访谈(N=4)。

主要发现

  • 共25,586例终末期肾病患者在440家透析机构接受治疗。
  • 干预后1年,对照组转诊率从11.2%降至9.2%,干预组从11.2%降至10.5%。
  • 黑人患者干预组与对照组转诊无显著差异(aOR 1.12,95%CI 0.94-1.33)。
  • 白人患者干预组转诊显著增加(OR 1.24,95%CI 1.02-1.51)。

临床怎么用

  • 多组分干预可能对部分人群转诊有改善,但需关注种族差异。
  • 实施大规模实用试验需考虑定制干预和联邦指令等挑战。

局限性

  • 转诊率整体下降趋势与全国趋势一致,可能影响干预效果评估。
  • 过程评估样本量较小(访谈N=4),实施挑战需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Declines in referral mirror national trends; however, declines were less for some groups receiving the intervention, warranting long-term follow-up. The findings provide important context for future modification and scale-up of multilevel, multicomponent interventions in dialysis settings. BACKGROUND: The Southeastern United States has among the lowest rates of kidney transplantation nationally and has documented racial and socioeconomic disparities in transplant access. We assessed the effectiveness and implementation of a multicomponent intervention aimed at increasing access and reducing disparities in access to early transplant steps in Georgia, North Carolina, and South Carolina. METHODS: The Reducing Disparities in Access to Kidney Transplantation Regional Study randomized 440 dialysis facilities in Georgia, North Carolina, and South Carolina to receive the Reducing Disparities in Access to Kidney Transplantation Regional educational and quality intervention or standard of care in 2018. The primary outcome was a change in dialysis facility-level transplant referral within 1 year of dialysis start after intervention, with secondary outcomes examining changes in evaluation start within 6 months of referral and waitlisting within 1 year of evaluation start. A process evaluation included a postimplementation survey ( N =220) and semistructured interviews of staff ( N =4). Generalized linear mixed-effects models assessed intervention effectiveness overall and in race subgroups. RESULTS: Among the 25,586 patients with ESKD treated in 440 dialysis facilities, referral rates decreased across both intervention arms 1 year after intervention; however, a greater decrease in referrals was observed among control (11.2% to 9.2%) versus intervention (11.2% to 10.5%) facilities. We observed no significant difference in the likelihood of referral among Black patients in intervention versus control facilities after intervention (adjusted odds ratio, 1.12; 95% confidence interval, 0.94 to 1.33); however, a significant increase in referral was observed among White patients in intervention facilities after intervention (odds ratio, 1.24; 95% confidence interval, 1.02 to 1.51). Interviews highlighted the importance of tailored interventions, federal mandates, and implementation challenges for large pragmatic trials. CONCLUSIONS: Postintervention declines in referral mirror national trends; however, these declines were less for some groups receiving the intervention, warranting long-term follow-up. These findings provide important context for future modification and scale-up of multilevel, multicomponent interventions in dialysis settings. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: The study protocol is available on ClinicalTrials.gov (identifier: NCT02389387 ).

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Patzer RE, Buford J, Urbanski M, et al. Reducing Disparities in Access to Kidney Transplantation Regional Study: A Randomized Trial in the Southeastern United States. Clin J Am Soc Nephrol. 2024. PMID: 39671258. doi:10.2215/CJN.0000000586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。